Summary
A combined eflornithine-MGBG treatment was studied in patients with acute myeloid leukemia (AML) or blastic transformation of chronic myeloid leukemia (BT CML). The first ten patients (5 AML, 5 BT CML) received i.v. or p.o. eflornithine 6 g m-2 day-1 and i.v. MGBG 500 mg/m2 once a week. The duration of treatment was 5–37 days (median 15) with one to five MGBG infusions (median 2). The results were complete response (CR) in one patient, partial response (PR) in four, minimal response (MR) in one and failure (F) in four. Pronounced side effects, including severe mucositis, gastrointestinal disturbances and skin infiltration, were observed in eight patients. As the four PRs were achieved in patients with BT CML, it was decided also to study ten patients with this indication. In attempts to decrease the incidence and severity of unwanted effects, lower doses of eflornithine-MGBG were used, i.e., eflornithine 4 g m-2 day-1 and MGBG 200 mg m-2 once a week. The duration of treatment was 9–110 days (median 46), with 2–14 MGBG infusions (median 6). Responses observed were CR in two patients (in one of whom it was only transient), transient PR in two, transient MR in four, and F in two. Treatment at lower doses was better tolerated, thus allowing a longer duration of treatment. Five of ten patients had moderate or severe gastrointestinal disturbances and one patient had a severe subjective hearing loss. The eflornithine-MGBG combination may prove to be a useful alternative treatment for AML and BT CML, but comparative trials will ultimately be necessary for a more definitive assessment of the combination.
References
Alhonen-Hongisto L, Seppänen P, Jänne J (1980) Intracellular putrescine and spermidine deprivation induces uptake of the natural polyamines and methylglyoxal bis (guanylhydrazone). Biochem J 192: 941–945
Baccarini M, Corbelli G, Tura S and the Italian Cooperative Study Group on chronic myeloid leukemia (1981) Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leuk Res 5: 149–157
Bernard J (1967) Acute leukemia treatment Cancer Res 27: 2565–2569
Boiron M, Jacquillat C, Weil M, Bernard J (1965) Combination of methylglyoxal bis (guanylhydrazone) (NSC-32946) and 6-mercaptopurine (NSC-755) in acute granulocytic leukemia. Cancer Chemother Rep 45: 69–73
Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B (1979) Results of treatment of Phl + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395
Freireich EJ, Frei E III, Karon M (1962) Methylglyoxal bis (guanylhydrazone): a new agent active against acute myelocytic leukemia. Cancer Chemother Rep 16: 183–186
Gastaut JA, Mascret B, Maraninchi D, Tubiana-Mathieu N, Carcassonne Y (1983) Treatment of acute leukemia with combined alpha-difluoromethyl-ornithine (alpha DFMO) and methyl-GAG in adult patients. Second European Conference on Clinical Oncology, Amsterdam 2–5 November
Goldman JM, Baughan A (1983) Application of bone marrow transplantation in chronic granulocytic leukemia. Clin Haematol 12: 739–753
Herman TS, Durie BG, Hutter JJ Jr (1982) Treatment of patients with refractory myelogenous leukemia with BCOMM (1,3-bis-chloro) (2-chloroethyl)-1-nitrosourea (BCNU), Oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methylglyoxal-bis-guanylhydrazone (MGBG). Cancer Chemother Pharmacol 8: 73–75
Jänne J, Alhonen-Hongisto L, Seppänen P, Simes M (1981) Use of polyamine antimetabolites in experimental tumors and in human leukemia. Med Biol 59: 448–457
Knight WA III, Fabian C, Costanzi JJ, Jones JJ, Coltman CA Jr (1983) Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A phase II trial of the Southwest Oncology Group. Invest New Drugs 1: 235–237
Kuhn JG, Knight WA III, McDaniel TM, Coltman CA Jr, Whitecar JP, Fabian C, Costanzi JJ (1982) Methylglyoxal-bis (guanylhydrazone) (methyl-GAG) in the management of non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1: 163
Letendre L, Kiely JM, Hoagland HC (1984) Reinduction chemotherapy for acute non lymphocytic leukemia. Mayo Clin Proc 59: 618–621
Levi JA, Wiernik PH (1975) Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute non-lymphocytic leukemia. Cancer Chemother Rep 59: 1043–1045
Levin RH Brittain GM, Freireich EJ (1963) Different patterns of remission in acute myelocytic leukemia: a comparison of the effects of methylglyoxal-bis-(guanylhydrazone) and 6-mercaptopurine. Blood 21: 689–698
Levin RH, Henderson E, Karon M, Freireich EJ (1964) Treatment of acute leukemia with methylglyoxal bis (guanylhydrazone) (methyl-GAG). Clin Pharmacol Ther 6: 31–42
Metcalf R, Bey P, Danzin C (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E. C. 4.1.1.17) by substrate and product analogues. J Am Chem Soc 100: 2551–2553
Schwarzenberg L, Schneider M, Cattant A, Amiel JL, Schlumberger JR, Mathé G (1966) Le traitement des leucémies aiguës par la methylglyoxal-bis (guanyl-hydrazone) et son association avec la 2-hydroxystilbamidine. Sem Hop Paris 42: 2955–2957
Seppänen P, Alhonen-Hongisto L, Jänne J (1981) Polyamine deprivation-induced enhanced uptake of methylglyoxal-bis-(guanylhydrazone) by tumor cells. Biochim Biophys Acta 674: 169–177
Simes M, Seppänen P, Alhonen-Hongisto L, Jänne J (1982) Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Int J Cancer 28: 567–570
Sjoerdsma A, Schechter PJ (1984) Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Ther 35: 287–300
Spiers AS (1979) Metamorphosis of chronic granulocytic leukemia: diagnosis, classification and management. Br J Haematol 41: 1–7
Splinter TAW, Romijn JC (1986) Phase I study of alpha-difluoromethylornithine and methyl-GAG. Eur J Cancer Clin Oncol 22: 61–67
Warrell RP Jr, Burchenal JH (1983) Methylglyoxal-bis (guanylhydrazone) (methyl-GAG): current status and future prospects. J Clin Oncol 1: 52–65
Warrell RP Jr, Straus DJ, Young CW (1982) Combination chemotherapy of patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26). Cancer Treat Rep 66: 1121–1125
Warrell RP Jr, Coonley CJ, Burchenal JH (1983) Sequential inhibition of polyamine synthesis. A phase I trial of DFMO (alpha-difluoromethylornithine) and methyl-GAG (methylglyoxal-bis [guanylhydrazone]) Cancer Chemother Pharmacol 11: 134–136
Wiernik PH (1984) The current status of therapy and prevention of blast crisis of chronic myelocytic leukemia. J Clin Oncol 2: 329–335
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gastaut, JA., Tell, G., Schechter, P.J. et al. Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG). Cancer Chemother. Pharmacol. 20, 344–348 (1987). https://doi.org/10.1007/BF00262590
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262590